Redeye only makes minor estimate changes, following Doro’s Q1’21 report. We maintain our valuation, even though Q1 Care sales were unsatisfactory. We have received higher conviction regarding our Care estimates due to the main Nordic competitor, Tunstall, being excluded from the new Swedish framework agreements, making Doro the king of the hill. This strengthens the spin-off case, in our view.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/